US4057685A
(en)
|
1972-02-02 |
1977-11-08 |
Abbott Laboratories |
Chemically modified endotoxin immunizing agent
|
US4356170A
(en)
|
1981-05-27 |
1982-10-26 |
Canadian Patents & Development Ltd. |
Immunogenic polysaccharide-protein conjugates
|
US4673574A
(en)
|
1981-08-31 |
1987-06-16 |
Anderson Porter W |
Immunogenic conjugates
|
SE8205892D0
(en)
|
1982-10-18 |
1982-10-18 |
Bror Morein |
IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
|
US4459286A
(en)
|
1983-01-31 |
1984-07-10 |
Merck & Co., Inc. |
Coupled H. influenzae type B vaccine
|
US4663160A
(en)
|
1983-03-14 |
1987-05-05 |
Miles Laboratories, Inc. |
Vaccines for gram-negative bacteria
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4761283A
(en)
|
1983-07-05 |
1988-08-02 |
The University Of Rochester |
Immunogenic conjugates
|
WO1995013796A1
(en)
|
1993-11-16 |
1995-05-26 |
Depotech Corporation |
Vesicles with controlled release of actives
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
US6090406A
(en)
|
1984-04-12 |
2000-07-18 |
The Liposome Company, Inc. |
Potentiation of immune responses with liposomal adjuvants
|
US5916588A
(en)
|
1984-04-12 |
1999-06-29 |
The Liposome Company, Inc. |
Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
|
US4695624A
(en)
|
1984-05-10 |
1987-09-22 |
Merck & Co., Inc. |
Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
|
US4882317A
(en)
|
1984-05-10 |
1989-11-21 |
Merck & Co., Inc. |
Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
|
US4808700A
(en)
|
1984-07-09 |
1989-02-28 |
Praxis Biologics, Inc. |
Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
|
IT1187753B
(en)
|
1985-07-05 |
1987-12-23 |
Sclavo Spa |
GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
US4680338A
(en)
|
1985-10-17 |
1987-07-14 |
Immunomedics, Inc. |
Bifunctional linker
|
US5011828A
(en)
|
1985-11-15 |
1991-04-30 |
Michael Goodman |
Immunostimulating guanine derivatives, compositions and methods
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
US5206152A
(en)
|
1988-04-08 |
1993-04-27 |
Arch Development Corporation |
Cloning and expression of early growth regulatory protein genes
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
NL8802046A
(en)
|
1988-08-18 |
1990-03-16 |
Gen Electric |
POLYMER MIXTURE WITH POLYESTER AND ALKANE SULFONATE, OBJECTS THEREFORE.
|
JPH04500203A
(en)
|
1988-08-25 |
1992-01-16 |
ザ リポソーム カンパニー,インコーポレイテッド |
Influenza vaccines and novel adjuvants
|
DE3841091A1
(en)
|
1988-12-07 |
1990-06-13 |
Behringwerke Ag |
SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
|
US5238944A
(en)
|
1988-12-15 |
1993-08-24 |
Riker Laboratories, Inc. |
Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
|
EP0378881B1
(en)
|
1989-01-17 |
1993-06-09 |
ENIRICERCHE S.p.A. |
Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
|
JP2752788B2
(en)
|
1989-01-23 |
1998-05-18 |
カイロン コーポレイション |
Recombinant therapy for infection and hyperproliferative disorders
|
DK0465529T3
(en)
|
1989-03-21 |
1998-10-05 |
Vical Inc |
Expression of exogenous polynucleotide sequences in a vertebrate
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
US4929624A
(en)
|
1989-03-23 |
1990-05-29 |
Minnesota Mining And Manufacturing Company |
Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
|
JPH0832638B2
(en)
|
1989-05-25 |
1996-03-29 |
カイロン コーポレイション |
Adjuvant formulation comprising submicron oil droplet emulsion
|
JPH04506662A
(en)
|
1989-07-14 |
1992-11-19 |
アメリカン・サイアナミド・カンパニー |
Cytokinin and hormone carriers for conjugate vaccines
|
EP0487587A1
(en)
|
1989-08-18 |
1992-06-03 |
Chiron Corporation |
Recombinant retroviruses delivering vector constructs to target cells
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
US4988815A
(en)
|
1989-10-26 |
1991-01-29 |
Riker Laboratories, Inc. |
3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
|
IT1237764B
(en)
|
1989-11-10 |
1993-06-17 |
Eniricerche Spa |
SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
|
ZA911974B
(en)
|
1990-03-21 |
1994-08-22 |
Res Dev Foundation |
Heterovesicular liposomes
|
US5658731A
(en)
|
1990-04-09 |
1997-08-19 |
Europaisches Laboratorium Fur Molekularbiologie |
2'-O-alkylnucleotides as well as polymers which contain such nucleotides
|
SE466259B
(en)
|
1990-05-31 |
1992-01-20 |
Arne Forsgren |
PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
|
US5149655A
(en)
|
1990-06-21 |
1992-09-22 |
Agracetus, Inc. |
Apparatus for genetic transformation
|
GB2276169A
(en)
|
1990-07-05 |
1994-09-21 |
Celltech Ltd |
Antibodies specific for carcinoembryonic antigen
|
ATE128628T1
(en)
|
1990-08-13 |
1995-10-15 |
American Cyanamid Co |
FIBER HEMAGGLUTININ FROM BORDETELLA PERTUSSIS AS A CARRIER FOR CONJUGATE VACCINE.
|
NZ239643A
(en)
*
|
1990-09-17 |
1996-05-28 |
North American Vaccine Inc |
Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
|
CA2098849C
(en)
|
1990-12-20 |
2007-07-10 |
Ralph R. Weichselbaum |
Control of gene expression by ionizing radiation
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
CZ285050B6
(en)
|
1991-03-01 |
1999-05-12 |
Minnesota Mining And Manufacturing Company |
1-SUBSTITUTED, 2-SUBSTITUTED-1H-IMIDAZO/4,5-c/QUINOLIN-4-AMINES, INTERMEDIATES FOR THEIR PREPARATION AND ANTIVIRAL PHARMACEUTICAL PREPARATIONS IN WHICH THEY ARE COMPRISED
|
JP3534749B2
(en)
|
1991-08-20 |
2004-06-07 |
アメリカ合衆国 |
Adenovirus-mediated gene transfer into the gastrointestinal tract
|
US5936076A
(en)
|
1991-08-29 |
1999-08-10 |
Kirin Beer Kabushiki Kaisha |
αgalactosylceramide derivatives
|
US5268376A
(en)
|
1991-09-04 |
1993-12-07 |
Minnesota Mining And Manufacturing Company |
1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
US5266575A
(en)
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
IT1262896B
(en)
|
1992-03-06 |
1996-07-22 |
|
CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
|
FR2688514A1
(en)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
|
IL105325A
(en)
|
1992-04-16 |
1996-11-14 |
Minnesota Mining & Mfg |
Immunogen/vaccine adjuvant composition
|
JPH07507689A
(en)
|
1992-06-08 |
1995-08-31 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Specific tissue targeting methods and compositions
|
EP0644946A4
(en)
|
1992-06-10 |
1997-03-12 |
Us Health |
Vector particles resistant to inactivation by human serum.
|
PT761231E
(en)
|
1992-06-25 |
2000-06-30 |
Smithkline Beecham Biolog |
COMPOSITION OF VACCINES CONTAINING ADJUVANTES
|
IL102687A
(en)
|
1992-07-30 |
1997-06-10 |
Yeda Res & Dev |
Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
EP0905253A3
(en)
|
1992-12-03 |
2000-11-02 |
Genzyme Corporation |
Adenoviral vector deleted of all E4-ORF except ORF6
|
US5395937A
(en)
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
EP1175912A1
(en)
|
1993-03-23 |
2002-01-30 |
SmithKline Beecham Biologics SA |
Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
|
US5759573A
(en)
|
1993-04-22 |
1998-06-02 |
Depotech Corporation |
Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
|
ATE304604T1
(en)
|
1993-06-24 |
2005-09-15 |
Frank L Graham |
ADENOVIRUS VECTORS FOR GENE THERAPY
|
US5352784A
(en)
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
WO1995002597A1
(en)
|
1993-07-15 |
1995-01-26 |
Minnesota Mining And Manufacturing Company |
IMIDAZO[4,5-c]PYRIDIN-4-AMINES
|
ATE440957T1
(en)
|
1993-09-15 |
2009-09-15 |
Novartis Vaccines & Diagnostic |
RECOMBINANT ALPHAVIRUS VECTORS
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
DE69434594T2
(en)
|
1993-10-25 |
2006-09-21 |
Canji, Inc., San Diego |
RECOMBINANT ADENOVIRUS VECTOR AND METHOD OF USE
|
WO1995011700A1
(en)
|
1993-10-29 |
1995-05-04 |
Pharmos Corp. |
Submicron emulsions as vaccine adjuvants
|
GB9326174D0
(en)
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
GB9326253D0
(en)
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
JP4303315B2
(en)
|
1994-05-09 |
2009-07-29 |
オックスフォード バイオメディカ(ユーケー)リミテッド |
Non-crossing retroviral vector
|
US6429199B1
(en)
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
US6239116B1
(en)
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
WO1996017072A2
(en)
|
1994-11-30 |
1996-06-06 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
US5482936A
(en)
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
UA56132C2
(en)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
|
GB9513261D0
(en)
|
1995-06-29 |
1995-09-06 |
Smithkline Beecham Biolog |
Vaccines
|
US5707829A
(en)
|
1995-08-11 |
1998-01-13 |
Genetics Institute, Inc. |
DNA sequences and secreted proteins encoded thereby
|
ATE424463T1
(en)
|
1996-05-06 |
2009-03-15 |
Oxford Biomedica Ltd |
RECOMBINATION-INCAPABLE RETROVIRAL VECTORS
|
US5770208A
(en)
|
1996-09-11 |
1998-06-23 |
Nabi |
Staphylococcus aureus B-linked hexosamine antigen
|
JP5087758B2
(en)
|
1997-03-10 |
2012-12-05 |
オタワ ホスピタル リサーチ インスティチュート |
Use of nucleic acids containing unmethylated CpG dinucleotides as adjuvants
|
US6818222B1
(en)
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
US6080725A
(en)
|
1997-05-20 |
2000-06-27 |
Galenica Pharmaceuticals, Inc. |
Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
|
GB9712347D0
(en)
|
1997-06-14 |
1997-08-13 |
Smithkline Beecham Biolog |
Vaccine
|
GB9713156D0
(en)
|
1997-06-20 |
1997-08-27 |
Microbiological Res Authority |
Vaccines
|
AU8586298A
(en)
|
1997-07-25 |
1999-02-16 |
University Of Massachusetts |
Designed protein pores as components for biosensors
|
EP0905243A2
(en)
*
|
1997-08-05 |
1999-03-31 |
Smithkline Beecham Corporation |
Polynucleotides from Staphylococcus aureus expressed in infected tissue
|
CA2302554C
(en)
|
1997-09-05 |
2007-04-10 |
Smithkline Beecham Biologicals S.A. |
Oil in water emulsions containing saponins
|
GB9725084D0
(en)
|
1997-11-28 |
1998-01-28 |
Medeva Europ Ltd |
Vaccine compositions
|
CN1200730C
(en)
|
1998-02-12 |
2005-05-11 |
惠氏控股有限公司 |
Pneumococcal and Meningococcal vaccines formulated with interleukin-12
|
US6303114B1
(en)
|
1998-03-05 |
2001-10-16 |
The Medical College Of Ohio |
IL-12 enhancement of immune responses to T-independent antigens
|
BR9909915A
(en)
|
1998-04-09 |
2000-12-26 |
Smithkline Beecham Biolog |
Adjuvant compositions
|
NZ508013A
(en)
|
1998-05-07 |
2003-08-29 |
Corixa Corp |
Adjuvant composition for use with an antigen in a vaccine composition
|
US6562798B1
(en)
|
1998-06-05 |
2003-05-13 |
Dynavax Technologies Corp. |
Immunostimulatory oligonucleotides with modified bases and methods of use thereof
|
US6110929A
(en)
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
GB9817052D0
(en)
|
1998-08-05 |
1998-09-30 |
Smithkline Beecham Biolog |
Vaccine
|
AU771330B2
(en)
|
1998-08-19 |
2004-03-18 |
Baxter Healthcare Sa |
Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
|
DE69935606T9
(en)
|
1998-10-16 |
2021-03-11 |
Glaxosmithkline Biologicals S.A. |
ADJUVANCE SYSTEMS AND VACCINE
|
AU1626199A
(en)
|
1998-12-04 |
2000-06-26 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
A vi-repa conjugate vaccine for immunization against salmonella typhi
|
US20030130212A1
(en)
|
1999-01-14 |
2003-07-10 |
Rossignol Daniel P. |
Administration of an anti-endotoxin drug by intravenous infusion
|
US6551600B2
(en)
|
1999-02-01 |
2003-04-22 |
Eisai Co., Ltd. |
Immunological adjuvant compounds compositions and methods of use thereof
|
ES2228467T3
(en)
|
1999-02-03 |
2005-04-16 |
Biosante Pharmaceuticals, Inc. |
THERAPEUTIC PARTICLES OF CALCIUM PHOSPHATE AND METHODS OF MANUFACTURE AND ITS USE.
|
MY125387A
(en)
|
1999-03-19 |
2006-07-31 |
Smithkline Beecham Biologicals S A |
Vaccine
|
AU781027B2
(en)
|
1999-04-09 |
2005-04-28 |
Department Of Health & Human Services |
Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
WO2001021152A1
(en)
|
1999-09-24 |
2001-03-29 |
Smithkline Beecham Biologicals S.A. |
Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
|
CA2383413A1
(en)
|
1999-09-24 |
2001-03-29 |
Smithkline Beecham Biologicals S.A. |
Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
|
EE200200158A
(en)
|
1999-09-25 |
2003-06-16 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acids
|
CA2396871A1
(en)
|
2000-01-20 |
2001-12-20 |
Ottawa Health Research Institute |
Immunostimulatory nucleic acids for inducing a th2 immune response
|
GB0007432D0
(en)
|
2000-03-27 |
2000-05-17 |
Microbiological Res Authority |
Proteins for use as carriers in conjugate vaccines
|
ES2334641T3
(en)
|
2000-09-01 |
2010-03-15 |
Novartis Vaccines And Diagnostics, Inc. |
AZA HETEROCICLIC DERIVATIVES AND THERAPEUTIC USE.
|
SG174632A1
(en)
|
2000-09-11 |
2011-10-28 |
Novartis Vaccines & Diagnostic |
Quinolinone derivatives
|
EP1322656B1
(en)
|
2000-09-26 |
2008-01-16 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
|
US6677348B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6660735B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
US6664264B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6677347B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
UA75622C2
(en)
|
2000-12-08 |
2006-05-15 |
3M Innovative Properties Co |
Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
|
US6667312B2
(en)
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6660747B2
(en)
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
AT410798B
(en)
*
|
2001-01-26 |
2003-07-25 |
Cistem Biotechnologies Gmbh |
METHOD FOR IDENTIFYING, ISOLATING AND PRODUCING ANTIGENS AGAINST A SPECIFIC PATHOGEN
|
GB0107661D0
(en)
*
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
US20030035806A1
(en)
|
2001-05-11 |
2003-02-20 |
D'ambra Anello J. |
Novel meningitis conjugate vaccine
|
WO2003020875A2
(en)
*
|
2001-06-17 |
2003-03-13 |
D-Squared Biotechnologies, Inc. |
Staphylococci surface-exposed immunogenic polypeptides
|
JP4516748B2
(en)
|
2001-09-14 |
2010-08-04 |
サイトス バイオテクノロジー アーゲー |
Packaging immunostimulatory substances in virus-like particles: preparation and use
|
JP4360906B2
(en)
|
2001-09-14 |
2009-11-11 |
サイトス バイオテクノロジー アーゲー |
In vivo activation of antigen-presenting cells to enhance the immune response induced by virus-like particles
|
WO2003035836A2
(en)
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
US7321033B2
(en)
|
2001-11-27 |
2008-01-22 |
Anadys Pharmaceuticals, Inc. |
3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
|
CN1300165C
(en)
|
2001-11-27 |
2007-02-14 |
安那迪斯药品股份有限公司 |
3-b-d-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
ES2336094T3
(en)
|
2002-03-29 |
2010-04-08 |
Novartis Vaccines And Diagnostics, Inc. |
BENZAZOLES REPLACED AND USE OF THE SAME AS INHIBITORS OF QUINASA RAF.
|
EP1511746A2
(en)
|
2002-05-29 |
2005-03-09 |
3M Innovative Properties Company |
Process for imidazo[4,5-c]pyridin-4-amines
|
JP2005533057A
(en)
|
2002-06-13 |
2005-11-04 |
ニューヨーク・ユニバーシティ |
Synthetic C-glycolipids and the use of synthetic C-glycolipids to treat cancer, infectious and autoimmune diseases
|
DE60333762D1
(en)
|
2002-08-23 |
2010-09-23 |
Novartis Vaccines & Diagnostic |
PYRROL COMPOUNDS AS GLYCOGENIC SYNTHASE KINASE 3 INHIBITORS
|
WO2004060308A2
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Thiosemicarbazones as anti-virals and immunopotentiators
|
EP1594524B1
(en)
|
2003-01-21 |
2012-08-15 |
Novartis Vaccines and Diagnostics, Inc. |
Use of tryptanthrin compounds for immune potentiation
|
GB0301554D0
(en)
|
2003-01-23 |
2003-02-26 |
Molecularnature Ltd |
Immunostimulatory compositions
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
CN1980692A
(en)
|
2003-07-24 |
2007-06-13 |
麦克公司 |
Polypeptides for inducing a protective immune response against staphylococcus aureus
|
RU2337108C2
(en)
*
|
2003-07-24 |
2008-10-27 |
Мерк Энд Ко., Инк. |
Polypeptides for induction of protective immune response against staphylococcus aureus
|
RU2236257C1
(en)
|
2003-09-15 |
2004-09-20 |
Косяков Константин Сергеевич |
Synthetic immunogen for therapy and prophylaxis of addiction with narcotic and psychoactive substances
|
US7771726B2
(en)
|
2003-10-08 |
2010-08-10 |
New York University |
Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
|
CN1918176A
(en)
|
2004-02-18 |
2007-02-21 |
默克公司 |
Polypeptides for inducing a protective immune response against staphylococcus aureus
|
US20070172498A1
(en)
|
2004-02-27 |
2007-07-26 |
Anderson Annaliesa S |
Polypeptides for inducing a protective immune response against staphyloococcus aureus
|
CA2560969A1
(en)
|
2004-03-31 |
2005-11-03 |
New York University |
Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
|
SI1742659T1
(en)
|
2004-04-05 |
2013-07-31 |
Zoetis P Llc |
Microfluidized oil-in-water emulsions and vaccine compositions
|
JP2008500043A
(en)
|
2004-05-25 |
2008-01-10 |
メルク エンド カムパニー インコーポレーテッド |
Polypeptides for inducing protective immune responses against Staphylococcus aureus
|
CA2579225A1
(en)
|
2004-09-17 |
2006-03-30 |
Merck & Co., Inc. |
Polypeptides for inducing a protective immune response against staphylococcus aureus
|
GB0421079D0
(en)
*
|
2004-09-22 |
2004-10-27 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
CA2583121A1
(en)
*
|
2004-10-21 |
2007-01-04 |
Wyeth |
Immunogenic compositions of staphylococcus epidermidis polypeptide antigens
|
EP1843785B1
(en)
|
2005-01-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Polypeptides for inducing a protective immune response against staphylococcus aureus
|
US20060228368A1
(en)
|
2005-04-07 |
2006-10-12 |
Nabi Biopharmaceuticals |
Method of protecting against staphylococcal infection
|
US20060228369A1
(en)
|
2005-04-11 |
2006-10-12 |
Program For Appropriate Technology In Health |
Stabilization and preservation of temperature-sensitive vaccines
|
US7691368B2
(en)
|
2005-04-15 |
2010-04-06 |
Merial Limited |
Vaccine formulations
|
NZ564606A
(en)
|
2005-06-27 |
2010-10-29 |
Glaxosmithkline Biolog Sa |
Immunogenic composition comprising atleast two N. meningitidis capsular polysaccharides conjugated through a linker protein
|
US8703095B2
(en)
|
2005-07-07 |
2014-04-22 |
Sanofi Pasteur S.A. |
Immuno-adjuvant emulsion
|
GB0526038D0
(en)
|
2005-12-21 |
2006-02-01 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
FR2896162B1
(en)
|
2006-01-13 |
2008-02-15 |
Sanofi Pasteur Sa |
EMULSION OIL IN THERMOREVERSIBLE WATER
|
EP1998800A2
(en)
|
2006-01-18 |
2008-12-10 |
University Of Chicago |
Compositions and methods related to staphylococcal bacterium proteins
|
AR060188A1
(en)
|
2006-03-30 |
2008-05-28 |
Glaxosmithkline Biolog Sa |
CONJUGATION PROCEDURE
|
JP2009531387A
(en)
|
2006-03-30 |
2009-09-03 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Immunogenic composition
|
WO2007145689A1
(en)
|
2006-06-12 |
2007-12-21 |
Nabi Biopharmaceuticals |
Use of alpha-toxin for treating and preventing staphylococcus infections
|
MX2009003325A
(en)
|
2006-10-12 |
2009-04-09 |
Glaxosmithkline Biolog Sa |
Vaccine comprising an oil in water emulsion adjuvant.
|
WO2008152447A2
(en)
|
2006-10-30 |
2008-12-18 |
The University Of Western Ontario |
Staphylococcus aureus specific anti-infectives
|
DE102006062398A1
(en)
|
2006-12-20 |
2008-06-26 |
Edi (Experimentelle & Diagnostische Immunologie) Gmbh |
Methods for detecting and / or characterizing cellular activity patterns, use of toll-like receptor ligands (TLR ligands) and a kit
|
GB0700136D0
(en)
*
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
WO2009029132A2
(en)
|
2007-05-31 |
2009-03-05 |
Merck & Co., Inc. |
Antigen-binding proteins targeting s. aureus orf0657n
|
CA2697538C
(en)
*
|
2007-08-31 |
2019-02-12 |
University Of Chicago |
Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
|
WO2010039563A2
(en)
|
2008-09-30 |
2010-04-08 |
University Of Maryland, Baltimore |
Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens
|
EP2208787A1
(en)
|
2009-01-19 |
2010-07-21 |
Université de Liège |
A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
|
BRPI1013780B8
(en)
*
|
2009-04-14 |
2022-10-04 |
Novartis Ag |
IMMUNOGENIC COMPOSITION USEFUL FOR IMMUNIZATION AGAINST STAPHYLOCOCCUS AUREUS, ITS PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION
|